Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Inhibition of sPLA2 in atherosclerotic plaque from coronary artery disease patient
Assay data:1 Active, 1 Activity ≤ 1 µM, 1 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Inhibition of sPLA2 in human HepG2 cells
Inhibition of sPLA2 in human plasma at 25 uM using 1-Hexadecanoyl-2-(1-pyrenedecanoyl)-sn-glycero-3-phosphomethanol as substrate preincubated for 10 mins followed by substrate addition measured after 90 mins by fluorescence assay
Assay data:1 Tested
SummaryPubMed CitationRelated BioAssays by Target
Inhibition of sPLA2 in human plasma using 1-Hexadecanoyl-2-(1-pyrenedecanoyl)-sn-glycero-3-phosphomethanol as substrate preincubated for 10 mins followed by substrate addition measured after 90 mins by fluorescence assay
Assay data:9 Active, 4 Activity ≤ 1 nM, 9 Activity ≤ 1 µM, 11 Tested
Ratio of XI50 for inhibition of human recombinant sPLA2 using PAPG to XI50 for inhibition of human recombinant sPLA2 using PAPC
Inhibition of human recombinant sPLA2 using PAPA as substrate assessed as reduction in free FA formation after 30 mins in presence of equal molar mixture of PAPA/PAPC/PAPE/PAPG/PAPS/PLPC by HPLC-MS analysis
Assay data:1 Active, 1 Activity ≤ 1 nM, 1 Activity ≤ 1 µM, 1 Tested
Inhibition of human recombinant sPLA2 using PAPS as substrate assessed as reduction in 16:0 LPS formation after 30 mins in presence of equal molar mixture of PAPA/PAPC/PAPE/PAPG/PAPS/PLPC by HPLC-MS analysis
Inhibition of human recombinant sPLA2 using PAPG as substrate assessed as reduction in 16:0 LPG formation after 30 mins in presence of equal molar mixture of PAPA/PAPC/PAPE/PAPG/PAPS/PLPC by HPLC-MS analysis
Inhibition of human recombinant sPLA2 using PAPE as substrate assessed as reduction in 16:0 LPE formation after 30 mins in presence of equal molar mixture of PAPA/PAPC/PAPE/PAPG/PAPS/PLPC by HPLC-MS analysis
Inhibition of human recombinant sPLA2 using PAPC as substrate assessed as reduction in 16:0 LPC formation after 30 mins in presence of equal molar mixture of PAPA/PAPC/PAPE/PAPG/PAPS/PLPC by HPLC-MS analysis
Inhibition of human recombinant sPLA2 using PAPA as substrate assessed as reduction in 16:0 LPA formation after 30 mins in presence of equal molar mixture of PAPA/PAPC/PAPE/PAPG/PAPS/PLPC by HPLC-MS analysis
Inhibition of human recombinant sPLA2 assessed as reduction in free FA formation after 30 mins by HPLC-MS analysis
Inhibition of human recombinant sPLA2 assessed as reduction in 16:0 LPC formation after 30 mins by HPLC-MS analysis
Inhibition of human sPLA2 at 10 uM relative to control
Inhibition of human sPLA2
RNAi screen for vemurafenib enhancer genes in BRAFV600 melanoma - Primary Screen
Assay data:790 Active, 18119 Tested
Summary
Human sPLA2-2D (Phospholipase A2)
Assay data:1 Active, 1 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by Target
Genome-wide siRNA screen of genes regulating the Lipopolysaccharide-induced TNF-alpha response in human macrophages_Primary screen TNF readout
Assay data:2853 Active, 18113 Tested
SummaryRelated BioAssays by Same Project
A screen to identify synthetic lethal interactions with E-cadherin in an MCF10A isogenic cell line
Assay data:2442 Active, 18052 Tested
SummaryPubMed Citation
A screen to identify genes that regulate lymphatic endothelial cell migration - Primary Screen
Assay data:1034 Active, 18120 Tested
SummaryRelated BioAssays by Depositor
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on